Institutions / Perceptive Advisors LLC

Perceptive Advisors LLC

CIK 1224962 · Institutionalso an insider · as of Mar 31, 2026
Portfolio value
$5.06B
Positions
92
As of
Mar 31, 2026

Portfolio trend

Portfolio value

$5.06B-7.3%
$5.46B$5.26B$5.06BQ4 '25Q1 '26

Positions

92-17.9%
11210292Q4 '25Q1 '26

Top holdings

Mar 31, 2026View all 92 →
CompanyClassValueShares% of portfolio
Praxis Precision Medicines, Inc.—$655.97M2,035,98613.0%
Celcuity Inc.CELCCommon Stock$356.94M3,127,2007.1%
Ascendis Pharma A/S—$350.28M1,531,4216.9%
Roivant Sciences Ltd.—$229.51M8,285,4614.5%
Centessa Pharmaceuticals PLC—$208.88M5,258,9034.1%
Rhythm Pharmaceuticals, Inc.—$206.45M2,373,7954.1%
Spyre Therapeutics, Inc.—$190.83M3,783,2253.8%
Nuvalent, Inc.—$161.92M1,580,5053.2%
Edgewise Therapeutics, Inc.—$139.36M4,423,9742.8%
Protagonist Therapeutics Inc—$129.73M1,230,8792.6%
Apogee Therapeutics, Inc.—$129.65M1,540,3842.6%
Travere Therapeutics, Inc.—$123.08M4,142,5512.4%
Amylyx Pharmaceuticals, Inc.—$115.16M8,284,8822.3%
Immatics N.V—$102.17M10,383,4562.0%
Relay Therapeutics, Inc.—$97.02M9,751,1411.9%
Inhibrx Biosciences, Inc.—$96.99M1,442,7071.9%
Meiragtx Hldgs PLC—$89.31M10,326,1031.8%
Zymeworks Inc.—$87.89M3,510,0781.7%
Solid Biosciences Inc.SLDBCommon Stock$85.73M11,906,6461.7%
Dyne Therapeutics, Inc.—$84.65M4,668,8391.7%
Biocryst Pharmaceuticals Inc—$70.77M7,434,0331.4%
Oruka Therapeutics, Inc.—$68.45M1,395,5011.4%
Artivion, Inc.—$59.96M1,637,2901.2%
Nurix Therapeutics, Inc.—$57.52M3,710,8771.1%
Nautilus Biotechnology, Inc.NAUTCommon Stock$48.87M12,594,2111.0%

Activity

Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
DateActionCompanyValueShares ΔPosition afterImpact
Q1 2026
as of
ExitExact Sciences Corp.$-121.92M-1.2M
-100.00%
—
high
Q1 2026
as of
AddAscendis Pharma A/S$102.93M+450K
+41.61%
1,531,421
6.92% of portfolio
high
Q1 2026
as of
ExitArcellx, Inc.$-95.59M-1.5M
-100.00%
—
high
Q1 2026
as of
ExitBoston Scientific Corp$-93.35M-979K
-100.00%
—
high
Q1 2026
as of
Add152309100$93.00M+2.3M
+80.25%
5,258,903
4.13% of portfolio
high
Q1 2026
as of
ExitAmicus Therapeutics Inc$-90.72M-6.4M
-100.00%
—
high
Q1 2026
as of
Exit04635X102$-84.89M-6.5M
-100.00%
—
high
Q1 2026
as of
AddRelay Therapeutics, Inc.$78.09M+7.8M
+412.34%
9,751,141
1.92% of portfolio
high
Q1 2026
as of
TrimApogee Therapeutics, Inc.$-66.52M-790K
-33.91%
1,540,384
2.56% of portfolio
high
Q1 2026
as of
ExitDanaher Corp /De$-45.78M-200K
-100.00%
—
medium

Insider transactions

Also files Forms 3 / 4 / 5
DateActionCompanyValueShares ΔPosition afterImpact
Dec 31, 2025OtherMGTX
MeiraGTx Holdings plc
Ordinary Shares
$18.19M-2.3M
-18.35%
10,231,103
10.65% of shares
low
Apr 17, 2026GrantMGTX
MeiraGTx Holdings plc
Ordinary Shares
$5.00M+556K
+5.43%
10,786,658
11.23% of shares
low
Jun 16, 2026GrantIMTX
Immatics N.V.
Stock Option (Right to Buy)
—+48K
48,000
0.04% of shares
low
Jun 11, 2026GrantMGTX
MeiraGTx Holdings plc
Restricted Share Units
—+60K
60,000
0.06% of shares
low
Jun 10, 2026GrantSLDB
Solid Biosciences Inc.
Director Stock Option (Right to Buy)
—+78K
77,500
0.07% of shares
low
Mar 25, 2026GrantMGTX
MeiraGTx Holdings plc
Warrant (Right to Buy)
—+300K
300,000
0.31% of shares
low
Mar 25, 2026GrantMGTX
MeiraGTx Holdings plc
Warrant (Right to Buy)
—+400K
400,000
0.42% of shares
low
Mar 25, 2026OtherMGTX
MeiraGTx Holdings plc
Warrant (Right to Buy)
—-300K
-100.00%
0
0.00% of shares
low
Mar 25, 2026OtherMGTX
MeiraGTx Holdings plc
Warrant (Right to Buy)
—-400K
-100.00%
0
0.00% of shares
low
Aug 2, 2022GrantMGTX
MeiraGTx Holdings plc
Warrant (Right to Buy)
—+300K
300,000
0.31% of shares
low